BioSpace News Archive

Business

ArQule Strengthens Executive Team with Two Key Appointments

Newly Created Positions of Senior Vice President, Corporate Strategy, Communication & Finance and Senior Vice President, Program Management and Product Planning

May 24, 2018
·
3 min read
Policy

Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin

Lupin Confirms Validity of OMIDRIA Patents

May 24, 2018
·
4 min read
FDA

XableCath Receives Second FDA Clearance for Its Peripheral Arterial Catheters

Company’s abrasion tip support catheter demonstrated safe and effective

May 24, 2018
·
2 min read
Deals

QT Vascular Enters Into Asset Purchase And Option Agreement With Teleflex

Teleflex will acquire the Company’s commercial coronary products and an option to purchase the drug coated Chocolate Heart™

May 24, 2018
·
2 min read
Pharm Country

New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation

The Janssen Pharmaceutical Companiesof Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with XARELTO® (rivaroxaban) over a two-year period compared to those taking warfarin.

May 24, 2018
·
16 min read
BioCapital

AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline

91 accepted abstracts at ASCO, including LYNPARZA® (olaparib) in prostate cancer and moxetumomab pasudotox in hairy cell leukemia

May 24, 2018
·
34 min read
Cxbladder™ Monitor Demonstrates Clinical Utility In Patients Being Monitored For Recurrent Bladder Cancer (UC)

The addition of Cxbladder Monitor for bladder cancer surveillance has been shown to enable physicians to reduce the overall number of diagnostic tests being ordered, potentially reducing the total cost of monitoring and reducing complications related to unnecessary tests.

May 24, 2018
·
6 min read
Drug Development

Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation

Treatment of agitation in the elderly in hospital and nursing home settings represents a rapid potential path to market for BNC210 No currently approved treatments and significant unmet medical need

May 24, 2018
·
6 min read